- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07671300
Superficial Vein Thrombosis Testing in the Emergency Department (SVTest)
Evaluating Superficial Vein Thrombosis in the Emergency Department.
Superficial vein thrombosis (SVT) occurs when blood in a vein directly under the skin clots. SVT causes vein tenderness, pain, and skin discolouration. Over time, the vein hardens into a firm, nontender, easily palpable lump. SVT commonly occurs in the veins of the leg. Each year, 1 per 1000 people over the age of 18 have SVT. SVT is painful but usually gets better within a month. Four in 100 people with SVT develop progressively worse blood clotting involving the deep veins or lungs.
If a deep vein clot in the leg occurs it can cause permanent disability with post-thrombotic syndrome (long-term leg pain and swelling) and reduced quality of life. If a pulmonary embolism occurs it may cause chest pain, breathlessness, pulmonary hypertension, psychological distress, and potentially death. Guidelines tell doctors to use ultrasound scanning to decide whether SVT needs treatment with a blood thinner or not. Blood thinners prevent the clot from worsening.
Many people who have SVT go to the emergency department. Scanning is limited to the daytime so often people have multiple trips to the emergency department for their scan and they spend many hours waiting for a doctor to see them. Our research group developed simple ways to limit the need for scans for other types of blood clots, like blood clots in the lungs or in the deep veins. We use a simple blood test called D-dimer. We believe we may be able to use D-dimer to help limit the need for SVT scanning.
This is an exploratory study to document what happens to patients tested for SVT in the emergency department, and to see if the D-dimer blood test might be useful in reducing scans. Our research group will review the emergency department charts for patients who came to the emergency department with SVT. Our results will tell us whether further studies would be helpful.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Natasha S Clayton
- Telefoonnummer: 416-566-3590
- E-mail: natasha.clayton@queensu.ca
Studie Contact Back-up
- Naam: de Wit, MD
Studie Locaties
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- Emergency Medicine
-
Contact:
- Natasha S Clayton
- Telefoonnummer: 416-566-3590
- E-mail: natasha.clayton@queensu.ca
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Aged ≥ 18
- Tested for superficial vein thrombosis in the emergency department or urgent care centre
- Patients tested for SVT at all sites, including arms, legs and torso
Exclusion Criteria:
- Patient opted out of research at the participating site
- Patient included in the study in the last 90 days
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Emergency department patients tested for superficial vein thrombosis
|
D-dimer blood test levels will be extracted from medical records.
This is an non-interventional study.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Superficial vein thrombosis, deep vein thrombosis and no thrombosis
Tijdsspanne: During index testing
|
SVT will be classified as a) situated within 3 cm of the deep vein junction, b) ≥ 5 cm in length and > 3 cm from the deep vein junction, and c) SVT < 5 cm in length and > 3 cm from the deep vein junction. Diagnosis of deep vein thrombosis and the finding of no thrombosis will be reported. |
During index testing
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
The secondary outcomes will the subsequent development of recurrent SVT, SVT propagation, deep vein thrombosis, pulmonary embolism, or death from pulmonary embolism among patients diagnosed with SVT at the index visit.
Tijdsspanne: 90 days
|
90 days
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Kerstin de Wit, MD, Kingston Health Sciences Centre
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CTO5894
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .